TargeTrust Biotech.

Real Early Cancer Screening, Detecting Cancer Therapy Resistance & Guiding Precision Dosing in Real-Time, and Universal Cancer-Specific Drugs 

 # Vision and Mission:

      Our products can greatly reduce the global cancer problem. The world’s only product and universal cancer-specific biomarker to:

1. Produce universal cancer-specific drugs to achieve universal precision cancer therapy.

2. Screen multiple early cancer to cut tumor away, making cancer cured easily.

3. Detect cancer therapy resistance in real-time. Guide correct therapy. Prevent patients from taking ineffective drugs.

4. Guide precision dosing in real-time. Reduce drug side-effects.

5. Detect early cancer relapse, to timely treat it.

6. Make real-time cancer action detection possible.

# Problems in Caner Treatment:

1. Most cancers are detected too late by current methods: Render cancer hard to treat.

2. Therapy resistance:30～70% treating drugs become ineffective; patients take ineffective drugs; delay therapy; hightly lethal.

3. Drug side-effects: Patients uncomfortable; may disrupt therapy; cause other diseseases; sometime lethal.

4. Current methods (CT, MRI, PET, CTC/ctDNA common liquid biopsy, traditional biomarkers, CancerSEEK, Grail MCED Test) assay cancer and cancer therapy response at cancer progression stage (increased tumor size, tumor invade other organs), these take many months, too late, delay therapy. The early cancer detection rates by current methods are low.

 # Our Solutions:    

     Tumor signal transductions stimulate cancer progression, it takes time less than 1 hour and continuously. We create a novel medical field "Tumor Signal Transduction-Liquid Biopsy" to assay tumor intracellular signal transduction in blood. It is the world's only method to assay cancer initiation, cancer progression, cancer relapse, therapy resistance, and guide precision dosing, in real-time. It makes real-time cancer action detection possible. 

#  We also develop the world's only universal cancer-specific biomarker to produce universal cancer-specific drugs to achieve universal precision cancer therapy. 

       Our inventions lead the future of cancer care, and open up a huge new pharmaceutical industry.

Our Invention-1: Tumor Signal Transduction-Liquid Biopsy

Competitive Analysis

1. Grail MCED Test and CancerSEEK  can detect 50 or 8 cancer types by assaying blood ctDNA. The sensitivity for stage I cancer detection range from 12% ～ 39% .

2.  Cancer assay with CancerSEEK and Grail MCED Test  are too late and delay therapy, because presence or increased ctDNA (circulating tumor DNA) indicate tumor growth, invasion, and therapy resistance occurred a long time ago. 

3. CancerSEEK and Grail MCED Test are a lab service, not a sellable product, thus are not widely available. 

Our Invention-2:  Universal Cancer-specific Biomarker    

        We develop the world’s only universal cancer-specific biomarker.

 p-CSE1L:

(1) It is highly expressed in most cancer types.

(2) It is a microvesicle membrane protein accumulated in tumor.

(3) Cancers have oncogenes which result in CSE1L phosphorylation.

(4) Tumor cells express oncogene thus have high p-CSE1L; normal cells don’t express oncogene, p-CSE1L is undetectable

Utility: To produce universal cancer-specific nanoparticle drugs and imaging agent to achieve universal precision cancer therapy:

1. Targeted contrast agent for image-guided precision cancer surgery.

2. Targeted imaging agent for precision radiotherapy.

3. Antibody-drug conjugates and peptide-drug conjugates.

4. Bispecific antibody.

5. Targeted liposome drugs.

6. Nanoparticles for targeted magnetic hyperthermia cancer therapy.

Advantages of Universal Cancer-Specific Drugs

1.   Universal cancer-specific drugs can increase therapy efficacy and reduce drug side-effects by minimizing normal cell damage.

2.   Universal cancer-specific drugs can reduce the timelines, costs, and improve drug accessibility by reducing the high attrition rates of new drug candidates in the developing process of traditional drugs.

3.   By developing drugs based on existing known universal cancer-specific biomarkers rather than starting from accidental encounters in screening candidate new drug, pharmaceutical companies can lower the finance and barriers associated with the development of traditional cancer drugs.

Contact: jiangmwd@gmail.com